Funding & VC

Onward Therapeutics Raises $28 Million Series B for Cancer Pipeline

Onward Therapeutics raised NT$900 million (~$28 million) in Series B funding to advance its bispecific antibody and NK cell therapy programs, with a Taipei Exchange listing targeted by end-2027.

By Amara Osei

3 min read

Onward Therapeutics Raises $28 Million To Advance Oncology Pipeline
Onward Therapeutics Raises $28 Million To Advance Oncology PipelineDarkoStojanovic / pixabay

What's News

  • Onward Therapeutics raised NT$900 million (~$28 million) in Series B; second closing in October 2026.
  • First raise since moving HQ from Switzerland to Taiwan in October 2025; prior rounds totaled CHF 75.5 million (~$90 million).
  • OT-A201 bispecific antibody has entered Phase 1b in solid tumors; Phase 1a blood cancer enrollment due to close by end-2026.
  • OT-C001 cord-blood NK cell therapy is in trials with rituximab in France for relapsed diffuse large B-cell lymphoma.
  • Company targets Taipei Exchange Emerging Stock Board registration by end of 2027.

Onward Therapeutics has raised NT$900 million, roughly $28 million, in Series B financing to push its clinical-stage cancer programs into later development and expand its Taiwan operations.

The round closed in two tranches, with the second landing in October 2026. It marks Onward's first capital raise since the company completed a share exchange and moved its global headquarters from Switzerland to Taiwan in October 2025. Before that transaction, Onward had raised CHF 75.5 million — about $90 million — across earlier rounds.

Who backed the round?

Existing shareholders CDIB Capital Healthcare Ventures and Hong Kong Chlitina International participated. New institutional investors included:

  • Beiley Biofund
  • Everbright Biofund
  • Test Rite International
  • Grand Fortune Venture Capital
  • Hercules Bioventure Partners
  • MitoBitTech Venture
  • Top Taiwan Venture Capital

Individual investors also joined the round.

Onward will deploy the cash across a pipeline holding two clinical-stage programs and two early discovery projects.

What does the money fund?

The lead asset, OT-A201, is a tetravalent bispecific antibody built to attack multiple mechanisms of tumor immune evasion and resistance. It has finished monotherapy dose escalation in solid tumors and moved into Phase 1b development. Planned work covers expansion cohorts in selected cancer types and combination regimens.

In blood cancers, Onward expects to complete enrollment in a Phase 1a study by the end of 2026. The company reported preliminary tumor responses and disease stabilization with what it called a manageable safety profile. Those are early clinical observations, and Onward says they need confirmation in additional trials.

The second clinical program, OT-C001, is an off-the-shelf natural killer cell therapy derived from umbilical cord blood. Investigators are testing it with rituximab in France in patients with diffuse large B-cell lymphoma who relapsed after, or didn't respond to, CAR-T and T-cell engager treatments.

Two early-stage projects round out the pipeline: an oncology metabolism program and an antibody targeting tumor-associated antigens.

What's next?

Chairperson and CEO Dr. C. Grace Yeh tied the raise directly to the company's new base. "This financing, our first since establishing our global headquarters in Taiwan, allows us to advance our clinical programs while building our R&D presence here," she said. "We are grateful for the continued support of our existing shareholders and welcome our new investors."

She also framed the commercial mission in patient terms: "Many patients with difficult-to-treat or relapsed cancers still have limited treatment options. We aim to bring them new options through different types of cancer therapies."

Dr. Armand de Gramont, President of Research and Development, set the scientific agenda: "Our priority is to translate innovative science into meaningful clinical results. By focusing on indications where our therapies have the greatest potential to overcome treatment resistance, we aim to build a differentiated oncology pipeline to deliver new treatment options for patients."

Onward is preparing to register on the Taipei Exchange's Emerging Stock Board by the end of 2027. It also plans to expand its Taiwan team and start local clinical trials — milestones that give the Series B investors a clear timeline for an exit path on the island's public market.

Source: pulse2.com

Share this article:

More from Amara Osei

Amara Osei

Show full bio

Senior reporter covering companies, deals and strategy in entrepreneurship, startups and venture funding at Business Bearings.

2,336 articles

Related articles

« Previous articleNext article »